Division of Cardiology, Department of Internal Medicine, Gwangju Veterans Hospital, Gwangju, Korea.
Korean Circ J. 2013 Oct;43(10):664-73. doi: 10.4070/kcj.2013.43.10.664. Epub 2013 Oct 30.
The high-sensitivity C-reactive protein (hs-CRP), a marker of inflammation, has been known to be elevated in patients with coronary artery disease. However, there is controversy about the predictive value of hs-CRP after acute myocardial infarction (MI). Therefore, we evaluated the impact of ischemic time on the predictive value of hs-CRP in ST-segment elevation myocardial infarction (STEMI) patients who were treated by primary percutaneous coronary intervention (PCI).
We enrolled 5123 STEMI patients treated by primary PCI from the Korean Working Group in Myocardial Infarction and divided enrolled patients into four groups by symptom-to-balloon time (SBT) and level of hs-CRP (Group I: SBT <6 hours and hs-CRP <3 mg/L, Group II: SBT <6 hours and hs-CRP ≥3 mg/L, Group III: SBT ≥6 hours and hs-CRP <3 mg/L, and Group IV: SBT ≥6 hours and hs-CRP ≥3 mg/L). To evaluate the impact of ischemic time on the predictive value of hs-CRP in STEMI patients, we compared the cumulative cardiac event-free survival rate between these four groups.
The sum of the cumulative incidence of all-cause mortality and recurrence of MI was higher in Group IV than in the other groups. However, there was no significant difference among Group I, Group II, and Group III. The Cox-regression analyses showed that an elevated level of hs-CRP (≥3 mg/L) was an independent predictor of long-term cardiovascular outcomes only among late-presenting STEMI patients (p=0.017, hazard ratio=2.462).
For STEMI patients with a long ischemic time (≥6 hours), an elevated level of hs-CRP is a poor prognostic factor of long-term cardiovascular outcomes.
高敏 C 反应蛋白(hs-CRP)是炎症的标志物,已被证实存在于冠心病患者中。然而,hs-CRP 在急性心肌梗死(MI)后的预测价值仍存在争议。因此,我们评估了缺血时间对接受直接经皮冠状动脉介入治疗(PCI)的 ST 段抬高型心肌梗死(STEMI)患者 hs-CRP 预测价值的影响。
我们纳入了 5123 例接受直接 PCI 治疗的 STEMI 患者,并根据症状至球囊时间(SBT)和 hs-CRP 水平将纳入的患者分为四组(I 组:SBT<6 小时且 hs-CRP<3mg/L;II 组:SBT<6 小时且 hs-CRP≥3mg/L;III 组:SBT≥6 小时且 hs-CRP<3mg/L;IV 组:SBT≥6 小时且 hs-CRP≥3mg/L)。为了评估缺血时间对 STEMI 患者 hs-CRP 预测价值的影响,我们比较了这四组患者的累积无心脏事件生存率。
与其他组相比,IV 组的全因死亡率和 MI 复发的累积发生率更高。然而,I 组、II 组和 III 组之间没有显著差异。Cox 回归分析显示,hs-CRP 水平升高(≥3mg/L)仅在迟发性 STEMI 患者中是长期心血管结局的独立预测因子(p=0.017,风险比=2.462)。
对于缺血时间较长(≥6 小时)的 STEMI 患者,hs-CRP 水平升高是长期心血管结局不良的预后因素。